Cargando…
Differentiated Thyroid Cancer: Management of Patients with Radioiodine Nonresponsive Disease
Differentiated thyroid carcinoma (papillary and follicular) has a favorable prognosis with an 85% 10-year survival. The patients that recur often require surgery and further radioactive iodine to render them disease-free. Five percent of thyroid cancer patients, however, will eventually succumb to t...
Autores principales: | Busaidy, Naifa Lamki, Cabanillas, Maria E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3316972/ https://www.ncbi.nlm.nih.gov/pubmed/22530159 http://dx.doi.org/10.1155/2012/618985 |
Ejemplares similares
-
Challenges Associated with Tyrosine Kinase Inhibitor Therapy for Metastatic Thyroid Cancer
por: Cabanillas, Maria E., et al.
Publicado: (2011) -
Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance
por: Hamidi, Sarah, et al.
Publicado: (2023) -
False-positive radioiodine uptake after radioiodine treatment in differentiated thyroid cancer
por: Barbaro, Daniele, et al.
Publicado: (2023) -
Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer
por: Petranović Ovčariček, Petra, et al.
Publicado: (2023) -
Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer
por: Herranz, Urbano Anido
Publicado: (2022)